DWA
ANAB icon

Dorsey Wright & Associates’s AnaptysBio ANAB Stock Holding History

Dorsey Wright & Associates’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,366
Closed -$34K – 271
2022
Q1 		$34K Sell
1,366
-182
-12% -$5.51K 0.01% 274
2021
Q4 		$54K Buy
+1,548
New +$49.1K 0.01% 225

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Dorsey Wright & Associates's ANAB Position: Q2 2022 in Review

Dorsey Wright & Associates sold out of AnaptysBio (ANAB) in Q2 2022, closing a stake of 1,366 shares — an estimated $34K sold.

Dorsey Wright & Associates first reported a position in ANAB in Q4 2021 and held it in 2 quarters. The position peaked at $54K in Q4 2021. 124 funds tracked by Wall St. Rank hold ANAB as of Q2 2022.

  • Dorsey Wright & Associates reported no remaining AnaptysBio position as of Q2 2022 after selling out during the quarter.
  • Dorsey Wright & Associates sold 1,366 AnaptysBio shares in Q2 2022, an estimated $34K.
  • Dorsey Wright & Associates first reported a position in AnaptysBio in Q4 2021 and held it in 2 quarters.
  • Dorsey Wright & Associates's AnaptysBio position peaked at $54K in Q4 2021.
  • 124 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2022.

Based on Dorsey Wright & Associates's 13F filing for Q2 2022, filed 20 Jul 2022.